Sun Pharmaceutical Industries has agreed to acquire Organon & Co., a company focused on women’s health, biosimilars, and established medicines, in a deal valued at approximately $11.75 billion, including debt. The transaction will bring Organon’s portfolio of more than 70 products under Sun Pharma, covering treatments distributed across about 140 countries. The portfolio includes a range of women’s health therapies as well as biosimilar and general medicines, alongside six manufacturing facilities located in Europe and emerging markets.
Organon was spun off from Merck in 2021 to manage specific segments, including women’s health, biosimilars, and established brands. The acquisition is expected to strengthen Sun Pharma’s presence in these therapeutic areas and broaden its access to global markets. Following completion, Sun Pharma is projected to become the seventh-largest biosimilar company worldwide. The addition of Organon’s portfolio is also expected to position the company among the top three firms globally in women’s health, according to company statements.
The deal also provides Sun Pharma with entry into biosimilars, complementing its existing focus on specialty medicines. In addition, it gives the company access to markets such as China, Brazil, and other emerging regions where its presence has been limited. Organon’s established portfolio and global distribution network are expected to add scale to Sun Pharma’s operations while maintaining a steady base of marketed products.
“This transaction is a logical next step in strengthening Sun Pharma’s global business,” said Managing Director Kirti Ganorkar. He added that the combined entity would aim to serve as a partner for acquiring and launching new products, while focusing on maintaining business continuity, integrating operations in a disciplined manner, and generating value.
Financially, the acquisition is structured as an all-cash transaction, with Sun Pharma offering $14 per share for Organon, representing a premium of more than 24% to the April 24 closing price. The deal is expected to close early next year, subject to customary conditions. Organon reported revenue of $6.2 billion for 2025 and carried net debt of about $8.6 billion as of the end of that year.
According to Shrikant Akolkar of Nuvama Institutional Equities, the addition of Organon’s business could double Sun Pharma’s revenue and EBITDA, with Organon contributing $6.2 billion in sales and margins of around 30%. He also indicated that the transaction is projected to be 30% to 40% accretive to earnings per share by fiscal year 2028. He further noted that the acquisition gives Sun Pharma access to markets where its presence has been limited, supporting its expansion as a branded and specialty drugs company.
Market reaction reflected the scale of the transaction. Sun Pharma’s shares rose 7% at close, increasing its market value by 271.36 billion rupees, after gaining as much as 9% earlier in the day. Organon’s shares climbed 16% in premarket trading to $14.06.
The acquisition will be funded through a combination of cash and committed bank financing. Organon had been examining strategic options as it carried significant debt, and the agreement follows that process.
Integration Challenges and Execution Strategy
Merging two large pharmaceutical organizations is never straightforward. The success of this deal will depend heavily on how effectively operations, supply chains, and corporate cultures are integrated. Aligning global manufacturing networks, regulatory frameworks, and commercial strategies across more than 100 markets will require careful planning and phased execution.
Leadership teams will likely prioritize maintaining business continuity while gradually unlocking synergies. This includes consolidating overlapping functions, optimizing procurement, and ensuring a smooth transition for employees and stakeholders.
Sun Pharma Redefines Global Strategy
The acquisition of Organon represents a defining moment for Sun Pharma. By strengthening its position in women’s health and biosimilars, Sun Pharma is not only expanding its global reach but also reshaping its future growth trajectory in the evolving pharmaceutical landscape.
Portfolio Diversification and Risk Management
One of the most important aspects of the deal is diversification. By combining established brands, specialty medicines, and emerging biologics, the merged entity reduces dependency on any single revenue stream.
